Simultaneous analysis of 29 synthetic cannabinoids and metabolites, amphetamines, and cannabinoids in human whole blood by liquid chromatography-tandem mass spectrometry - A New Zealand perspective of use in 2018
Simultaneous analysis of 29 synthetic cannabinoids and metabolites, amphetamines, and cannabinoids in human whole blood by liquid chromatography-tandem mass spectrometry - A New Zealand perspective of use in 2018
复制标题
DOI：
10.1002/dta.2697
复制
发表时间：
2019-11-28
影响因子：
2.9
通讯作者：
McCarthy, Mary-Jane
中科院分区：
文献类型：
--
作者：
Ong, Rui Shen;Kappatos, Diana C.;McCarthy, Mary-Jane
我们描述了同时分析人全血中 29 种合成大麻素 (SC) 和代谢物、4 种安非他明和 2 种大麻素的方法的验证。这种方法使一次分析能够涵盖以前对这些具有不同理化性质的经典和新型滥用药物所需的多次分析。目标分析物的范围基于 2017 年新西兰边境最常见的滥用药物和 SC，包括属于吲哚和吲唑甲酰胺、喹啉基吲哚羧酸酯和萘甲酰吲哚分类的母体化合物和代谢物。通过支持液体萃取 (SLE) 制备样品，然后进行液相色谱-串联质谱 (LC-MS/MS) 分析和正电喷雾电离 (ESI)。该方法在选择性、基质效应、工艺效率、灵敏度、重复性、提取物稳定性和残留量方面进行了验证，以进行定性确认。还评估了目标决策浓度的线性以及准确性和精密度数据。检测限和确认限分别为 0.1 至 6.0 ng/mL 和 1.0 至 6.0 ng/mL。所述方法成功应用于2018年564份死前和死后血液样本的分析。有132例（23%）至少有一种SC呈阳性结果，其中五种最常见的SC是AMB-FUBINACA和/或酸（61%）、5F-ADB和/或酸（40%）、ADB-FUBINACA（11%）、5F-MDMB-PICA酸(6%) 和 MDMB-FUBINACA 酸 (6%)。结果还表明，血液中主要存在比未改变的母体 SC 更高水平的代谢物，这突出表明需要维持能够同时检测母体化合物和代谢物的法医筛选方法。
We describe the validation of a method for the simultaneous analysis of 29 synthetic cannabinoids (SCs) and metabolites, 4 amphetamines, and 2 cannabinoids in human whole blood. This method enables one analysis to cover what previously required multiple analyses for these classic and novel drugs-of-abuse with diverse physicochemical properties. The scope of targeted analytes was based on the most prevalent drugs-of-abuse and SCs encountered at the New Zealand border in 2017 and included parent compounds and metabolites belonging to the indole and indazole carboxamide, quinolinyl indole carboxylate, and naphthoylindole classifications. Samples were prepared by supported-liquid-extraction (SLE) followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis with positive electrospray ionization (ESI). The method was validated with respect to selectivity, matrix effects, process efficiency, sensitivity, repeatability, extract stability, and carryover for qualitative confirmation. Linearity as well as accuracy and precision data at target decision concentrations were also evaluated. The limits of detection and confirmation ranged from 0.1 to 6.0 ng/mL and 1.0 to 6.0 ng/mL, respectively. The described method was successfully applied to the analysis of 564 ante- and post-mortem blood samples in 2018. There were 132 cases (23%) with positive findings of at least one SC, with the five most commonly detected SCs being AMB-FUBINACA and/or acid (61%), 5F-ADB and/or acid (40%), ADB-FUBINACA (11%), 5F-MDMB-PICA acid (6%), and MDMB-FUBINACA acid (6%). The results also demonstrate the predominant presence of metabolites at higher levels than the unchanged parent SCs in blood, highlighting the need to maintain forensic screening methods capable of the simultaneous detection of both parent compounds and metabolites.